Clinical effect of everolimus and somatostatin analogues as a first line therapy for patients with pNET (phase II study)

Trial Profile

Clinical effect of everolimus and somatostatin analogues as a first line therapy for patients with pNET (phase II study)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2013

At a glance

  • Drugs Everolimus (Primary) ; Somatostatins (Primary)
  • Indications Primitive neuroectodermal tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Apr 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top